Company profile
RegeneRx Biopharmaceuticals, Inc.
OTC: RGRX · Healthcare · Biotechnology
#1060 of 1,422 Healthcare companies by revenue41st-percentile growth
EA Score
——FH —DQ 38GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ growth stability, listing tenure · ↓ market scale, workforce scale
Methodology →Revenue TTM
$76.8k
Rev growth YoY (TTM)
-0.0%
Net income (FY)
-$1.7M
Employees
2
as of 2026-07-12
Market cap
$898
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$76.8k$76.8k2022
Net income-$1.7M-$1.7M2022
Operating income-$1.4M-$1.4M2022
Total assets$382.2k$382.2k2022
Liabilities$3.8M$3.8M2022
Equity-$3.4M-$3.4M2022
Revenue trend
FY2015 – FY2022 · USD
FY15
FY16
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is RegeneRx Biopharmaceuticals, Inc.’s revenue?
RegeneRx Biopharmaceuticals, Inc. booked $76.8k in FY2022 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -2250.4% net margin.
Peers · Healthcare
Xebra Brands Ltd.——Imaging Dynamics Company Ltd.31DNemaura Medical Inc.——Sky Century Investment, Inc.28DAclarion, Inc.36DSilo Pharma, Inc.39DNeighbors
Montgomery →Key facts
CEOJ. J. Finkelstein
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeOTC: RGRX
Employees2
IPO date2003-10-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.